Gene: MYLK2

85366
KMLC|MLCK|MLCK2|skMLCK
myosin light chain kinase 2
protein-coding
20q11.21
Ensembl:ENSG00000101306 MIM:606566 Vega:OTTHUMG00000032194 UniprotKB:Q9H1R3
NG_012847.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.089e-1 (AD)  2.498e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLC38A50.712
SEMA3G0.676
TMEM880.649
CLEC3B0.629
FOXS10.627
PROM10.625
LIMS20.625
ITIH50.616
CCM2L0.615
EDN30.607

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SNX31-0.434
MIA-0.413
THAP2-0.411
SPR-0.406
ANGPTL4-0.405
TDRG1-0.38
NPC1L1-0.378
C7orf61-0.378
CCNA2-0.374
SERPINA3-0.372

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB04825PrenylamineSmall Molecule390-64-7WithdrawnTarget
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MYLK2 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MYLK2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MYLK2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MYLK2 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MYLK2 mRNA"25510870
D020106AcrylamideAcrylamide results in increased expression of MYLK2 mRNA28959563
D000638AmiodaroneAmiodarone results in increased expression of MYLK2 mRNA19774075
D000643Ammonium ChlorideAmmonium Chloride affects the expression of MYLK2 mRNA16483693
D001280AtrazineAtrazine results in increased expression of MYLK2 mRNA22378314
C006780bisphenol Abisphenol A affects the expression of MYLK2 mRNA21786754
C006780bisphenol Abisphenol A results in decreased methylation of MYLK2 promoter27312807
C006780bisphenol Abisphenol A results in decreased expression of MYLK2 mRNA25181051
D002251Carbon TetrachlorideCarbon Tetrachloride results in decreased expression of MYLK2 mRNA16239168
D003907DexamethasoneDexamethasone results in increased expression of MYLK2 mRNA22733784
D004041Dietary FatsDietary Fats results in decreased expression of MYLK2 mRNA18042831
D004051Diethylhexyl PhthalateDiethylhexyl Phthalate results in increased expression of MYLK2 mRNA28085963
C069837fullerene C60fullerene C60 results in decreased expression of MYLK2 mRNA19167457
D019833Genistein[Genistein co-treated with vinclozolin] results in increased expression of MYLK2 mRNA23160963
D019833GenisteinGenistein results in increased expression of MYLK2 mRNA23160963
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of MYLK2 mRNA24796395
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of MYLK2 mRNA"24972896
C056218ML 9ML 9 results in decreased activity of MYLK2 protein12534346
C028007nickel monoxidenickel monoxide results in increased expression of MYLK2 mRNA19167457
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of MYLK2 mRNA25729387
C030110oxaliplatinoxaliplatin results in decreased expression of MYLK2 mRNA25729387
D000073878Palm OilPalm Oil results in decreased expression of MYLK2 mRNA18042831
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MYLK2 mRNA"25510870
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of MYLK2 mRNA19162173
D010936Plant ExtractsPlant Extracts results in decreased expression of MYLK2 mRNA23557933
D011441PropylthiouracilPropylthiouracil results in decreased expression of MYLK2 mRNA24780913
D012822Silicon DioxideSilicon Dioxide results in increased expression of MYLK2 mRNA22431001
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of MYLK2 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of MYLK2 mRNA25729387
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of MYLK2 mRNA"26179874
C025643vinclozolin[Genistein co-treated with vinclozolin] results in increased expression of MYLK2 mRNA23160963
C025643vinclozolinvinclozolin results in increased expression of MYLK2 mRNA23160963

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004683calmodulin-dependent protein kinase activity-ISS-  
GO:0004687myosin light chain kinase activity-IBA21873635  
GO:0004687myosin light chain kinase activity-IDA16448786  
GO:0004687myosin light chain kinase activity-ISS-  
GO:0005515protein binding-IPI21556048  
GO:0005516calmodulin binding-IC16448786  
GO:0005516calmodulin binding-ISS-  
GO:0005524ATP binding-IEA-  
GO:0032027myosin light chain binding-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0006941striated muscle contraction-IBA21873635  
GO:0006941striated muscle contraction-IDA16448786  
GO:0007274neuromuscular synaptic transmission-IEA-  
GO:0010628positive regulation of gene expression-IDA21556048  
GO:0014816skeletal muscle satellite cell differentiation-IEA-  
GO:0018107peptidyl-threonine phosphorylation-IDA21556048  
GO:0032971regulation of muscle filament sliding-IDA16448786  
GO:0035914skeletal muscle cell differentiation-IDA21556048  
GO:0046777protein autophosphorylation-IDA21556048  
GO:0048769sarcomerogenesis-IBA21873635  
GO:0055003cardiac myofibril assembly-IBA21873635  
GO:0055008cardiac muscle tissue morphogenesis-IBA21873635  
GO:0055008cardiac muscle tissue morphogenesis-IMP16448786  
GO:0060048cardiac muscle contraction-IC16448786  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA21556048  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA21556048  
GO:0030017sarcomere-IC16448786  
KEGG ID KEGG Term
hsa04020Calcium signaling pathway
hsa04270Vascular smooth muscle contraction
hsa04510Focal adhesion
hsa04810Regulation of actin cytoskeleton
hsa04971Gastric acid secretion
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28814982Cord blood DNA methylation and adiposity measures in early and mid-childhood. (2017)Kresovich JKClin Epigenetics